CRVS - Corvus Pharmaceuticals EPS misses by $0.03 November, 01 2021 05:14 PM Corvus Pharmaceuticals Inc. Corvus Pharmaceuticals (NASDAQ:CRVS): Q3 GAAP EPS of -$0.24 misses by $0.03. Cash, cash equivalents and marketable securities totaling $76.3M. Press Release For further details see: Corvus Pharmaceuticals EPS misses by $0.03